Postafen

Quick links to important sections

Postafen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Postafen

Postafen is a medicinal product containing the active ingredient Buclizine, which belongs to the class of first-generation antihistamines. This single-ingredient, synthetic compound is manufactured for oral administration and is used to target symptoms arising from overstimulation of the body's balance and vomiting centers.


Property Description
Active ingredient Buclizine hydrochloride
Form Oral tablet
Pharmacological class H₁ receptor antagonist (Antihistamine)
Common use Relief of dizziness and nausea (e.g., in motion sickness)
Origin Synthetic compound (Piperazine derivative)

What Type of Medicine Is Postafen?

Postafen is a synthetic pharmaceutical entity classified as an H₁ receptor antagonist. This pharmacological class falls under the group of piperazine derivatives. Being a first-generation antihistamine, Buclizine is characterized by its ability to readily cross the blood-brain barrier. This property allows its actions on central structures in the brain.

Composition, Form, and Origin

The core component of the medicine is Buclizine hydrochloride, a synthetic substance prepared for systemic delivery. Postafen is typically presented as a solid oral tablet that delivers a single active ingredient alongside inactive pharmaceutical excipients. As a synthetic chemical compound, Buclizine’s origin is entirely artificial. This compound works by suppressing the pathways that cause feelings of nausea and motion sickness. This action demonstrates that the medication helps ease discomfort by stabilizing the nervous signals that lead to feeling unwell, particularly when experiencing situations such as prolonged car travel.

General Purpose and Primary Benefit

The general purpose of Postafen is to prevent or alleviate physical symptoms related to motion and imbalance, such as dizziness, vertigo, and nausea. This primary benefit is achieved because Buclizine acts centrally to depress labyrinth excitability and inhibit vestibular stimulation. Its mechanism relies on this central activity to calm the overactive signaling between the inner ear and the brain that leads to feelings of sickness and spinning.

What side effects are possible with Postafen?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse reactions and safety constraints for the active ingredient Buclizine, strictly based on regulatory documents from government health authorities.

Documented Adverse Reactions by System-Organ Class

The official safety profile organizes potential side effects based on the body systems affected. While specific frequency classifications (such as 'Common' or 'Rare') are not uniformly applied to all listed reactions in regulatory summaries, the following system classes are associated with documented adverse events:

System-Organ Class Examples of Documented Reactions
Nervous System Disorders Drowsiness, dizziness, headache, incoordination.
Gastrointestinal Disorders Dry mouth, nausea, vomiting, epigastric pain.
Eye Disorders Blurred vision.
Renal and Urinary Disorders Urinary retention.
Skin and Subcutaneous Tissue Disorders Skin rash.

Official Safety Constraints and Special Populations

Certain constraints and warnings are required in official prescribing information due to Buclizine's pharmacological properties. These do not constitute medical advice, but reflect limitations documented by health authorities:

  • Serious Adverse Reactions: Clinically significant reactions documented in official listings include convulsions (seizures).
  • Absolute Contraindications: The medicine is explicitly contraindicated for use in neonates and in individuals with known hypersensitivity to Buclizine.
  • Use with Caution: Caution is documented for individuals with pre-existing conditions such as Glaucoma, Prostatic Hypertrophy (due to the risk of urinary retention), Hepatic Impairment, and Renal Impairment.
  • Ability Impairment: An official warning exists regarding the potential for drowsiness and dizziness, which may impair the ability to drive or operate dangerous machinery.

The regulatory safety information emphasizes that concomitant use with alcohol or other CNS depressants can potentiate the effects of Buclizine.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Postafen (meclizine) is characterized by effects on the Central Nervous System (CNS) and the Anticholinergic system. Ingesting significantly more than the recommended dose requires immediate medical attention.

Documented Overdose Presentations

Symptoms of overdose may include severe CNS depression, presenting as extreme drowsiness, confusion, and hallucinations. These effects can potentially progress to serious outcomes like seizures and coma, particularly with massive ingestions.

Other physiological effects are related to the drug's anticholinergic properties. These can manifest as dilated pupils, fever, flushing of the skin, dry mouth, and difficulty urinating. Cardiovascular signs may also appear, including a rapid heartbeat (tachycardia) or low blood pressure (hypotension), which may be more pronounced in elderly individuals.

Emergency Action and Population Considerations

Immediate medical attention is required in the event of a suspected overdose. The official instruction is to contact a poison control center or call emergency services right away, especially if the person has collapsed, is having a seizure, or cannot be awakened.

There is no specific antidote for meclizine overdose; therefore, treatment is entirely supportive and symptomatic, focused on managing the clinical manifestations and preventing further drug absorption. In children, CNS effects may present differently, with greater likelihood of stimulation, characterized by agitation, hallucinations, and seizures, mandating prompt and specialized care.

Therapeutic Uses of Postafen

What Postafen Treats: Main Uses and Benefits

Postafen is commonly used in areas where short-term symptom management is appropriate, applied across domains where additional symptomatic support is needed. It is considered relevant for easing symptoms that interfere with daily functioning, particularly those associated with systemic imbalance and motion. This makes it applicable in managing conditions characterized by acute or disruptive episodes.

The medicine helps address symptom clusters related to vestibular disturbances, such as vertigo and dizziness associated with acute or episodic changes, and symptoms related to physical discomfort like nausea and vomiting associated with travel. It is also relevant for easing allergic symptoms, including a runny nose and sneezing.

“It supports the patient by easing distress related to both systemic imbalance and heightened physiological activity.”

Quick Fact: Relief for Motion-Induced Distress

Postafen is commonly used across contexts where symptoms related to physical discomfort are linked to movement. It is applied when symptoms create noticeable physiological strain, and supports improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Eligibility for Use

Postafen (meclizine hydrochloride) is contraindicated in any individual who has a known hypersensitivity or allergic reaction to meclizine or any of the inactive ingredients in the formulation. This represents an absolute non-eligibility for use.

Use is not recommended for children younger than 12 years of age, as clinical studies to establish the safety and effectiveness profile in this pediatric population have not been sufficiently conducted.

Restricted Use and Cautions

Official regulatory labeling specifies that the medicine should be administered with caution in patients with certain pre-existing medical conditions due to the drug’s potential anticholinergic effects. These conditions include:

  • Glaucoma
  • Asthma or other breathing issues
  • Enlargement of the prostate gland (or other urination problems)

Additionally, use requires caution in patients with hepatic (liver) impairment or renal (kidney) impairment, including the elderly population, due to the potential for the drug or its metabolites to accumulate in the body.

For pregnancy, the drug is classified as a former Pregnancy Category B. Use is typically considered only if clearly necessary after weighing benefits and risks. For lactating (nursing) mothers, caution is advised as it is not known whether the drug is excreted into human milk.

What should I know about interactions with other medicines?

This section describes the officially documented interaction patterns for Postafen (Buclizine) as outlined in government regulatory prescribing information. The profile is defined primarily by pharmacodynamic reinforcement concerning central nervous system (CNS) and anticholinergic activities.

Interactions Leading to Additive CNS Depression

Co-administration with other medicinal products classified as CNS depressants may lead to an additive sedative effect, as explicitly detailed in regulatory documents. These interacting categories include, but are not limited to, sedatives, hypnotics, general anesthetics, certain anti-psychotics, and centrally acting muscle relaxants. The consumption of alcohol (ethanol) is also specifically documented in official labeling to enhance the sedative effects of Buclizine. No timing-based interaction rules requiring mandatory dose separation are provided.

Interactions Leading to Additive Anticholinergic Action

Buclizine exhibits inherent anticholinergic activity. Co-administration with other medicinal products that share this pharmacological property may result in an additive antimuscarinic action. This pharmacodynamic interaction is noted in regulatory sources for classes such as tricyclic antidepressants, Monoamine Oxidase Inhibitors (MAOIs), and atropine-like compounds.

Absence of Documented Pharmacokinetic Interactions

Official regulatory summaries from government sources do not contain explicit documentation of clinically significant pharmacokinetic interactions involving Buclizine’s metabolic pathways, such as Cytochrome P450 enzyme inhibition or induction, or drug transporter activity. No combinations are formally classified as contraindicated solely due to interaction risk.

Mechanism of Action

Central Neurotransmitter Blockade and System Dampening

The drug's primary mechanism involves the antagonism (blocking) of two critical signaling molecules in the brain: the Histamine H1 receptor and the Muscarinic Acetylcholine (M1) receptor. These receptors are located in the brainstem, specifically within the vestibular nuclei and the vomiting center . This dual blockade acts to suppress the flow of excitatory signals originating from the inner ear's balance apparatus.


Modulating the Emetic Reflex Pathway

By inhibiting the H1 and M1 receptors, the drug disrupts the Vestibular-Emetic Pathway, which is the signal cascade that triggers efferent output. This targeted pathway interference raises the neurological threshold required to activate the central vomiting reflex. The resulting physiological effect is a dampened central response to motion stimuli, reducing the central processing of high-frequency signaling from the vestibular apparatus.

Dosage and Administration Information

How to Use Postafen: Official Administration Guidelines

Administration of Postafen (Buclizine hydrochloride) is guided by standardized procedures. These instructions govern the dosage, timing, and approved route to ensure correct usage, focusing on acute, as-needed administration patterns.


Administration Scope

Field Official Instruction
Route of administration The approved route is oral administration using the tablet form.
Dosing schedule The standard initial adult dose is typically 50 mg for acute, prophylactic use.
Timing in relation to activity The initial dose is administered approximately one hour prior to the anticipated start of the activity (e.g., travel) to achieve a preemptive effect.
Preparation requirements The oral tablet is generally intended to be swallowed whole.
Age-group rules A reduced initial dose of 6.25 mg is specified for children aged 12 to 15 years.

Instruction Classifications

Classification Pattern
Administration method type Oral
Frequency pattern As-needed (on-demand) and prophylactic use.
Use-context constraints Treatment is generally defined as short-term, with continuous use often limited to a few consecutive days.

Resulting Procedural Structure

The standard instruction protocol establishes a precise use pattern:

  • The full, specified dose must be taken one hour before the start of the activity.
  • The oral tablet is to be swallowed whole.
  • Dosing frequency is constrained by the drug's duration of action, which is typically specified as approximately six hours, limiting how often subsequent doses may be considered.

The overall use protocol is defined by this acute, non-daily regimen, which focuses on preemptive dosing and adherence to established milligram limits and age-based rules.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Postafen

The research into Buclizine, and the antihistamine class it belongs to, has primarily explored symptom changes related to motion and travel. Studies used Randomized Controlled Trials (RCTs) and systematic reviews to examine outcomes related to physical discomfort, such as nausea severity and the frequency of vomiting, typically focusing on healthy adult populations. Findings describe group patterns observed during the short-term prevention and management of these acute symptoms.


Research also explored short-term symptom patterns of vertigo and dizziness that arise from vestibular disorders. The evidence base includes RCTs comparing Buclizine's analogues against other symptomatic treatments. Reported findings described patterns related to changes measured during the initial, acute phase of heightened symptom activity. Research describes that the use of this class of medication was observed to focus only on acute symptom patterns; studies suggest chronic use was associated with potential effects on the body's natural compensation process.


A key limitation across the research is that follow-up durations were limited, typically assessing outcomes within the first few days. Consequently, long-term effects are not fully established, and certainty remains low regarding the consequences of continuous, prolonged use for both motion sickness and vertigo. The study populations examined were primarily adults, and while clinical guidelines sometimes apply to individuals over 12 years of age, specific data for children remain insufficient. Research on the Buclizine molecule itself may be limited, even though the broader antihistamine class has been explored in numerous trials.

Frequently Asked Questions (FAQ)

Common questions about Postafen (FAQ)


Q: Is Postafen mainly used just for motion sickness?

A: The active ingredient in Postafen, Buclizine/Meclizine, is indicated for more than just motion sickness. Official information indicates its uses include the prevention and treatment of nausea, vomiting, and dizziness. It is also utilized in the management of symptoms associated with vertigo.


Q: Is drowsiness or tiredness a very common side effect of Postafen?

A: Official regulatory labels list drowsiness and fatigue as documented adverse reactions. However, specific frequency classifications, such as 'very common,' are not uniformly provided for all documented effects in all official product information. Drowsiness is a known potential effect of this class of medicine.


Q: Can Postafen cause dry mouth or constipation?

A: Dry mouth is a commonly documented side effect of Postafen's active ingredient. Constipation is also listed as a potential side effect in sources describing its anticholinergic properties (the way it works on certain signals in the body).


Q: Can Postafen affect your ability to concentrate?

A: Due to the potential for side effects like dizziness and drowsiness, regulatory warnings exist regarding tasks that require high mental alertness. Official information indicates these effects may impair the ability to perform activities such as driving or operating machinery. Some product information explicitly lists difficulty in concentrating as a potential reaction.


Q: Can Postafen tablets be crushed or split in half?

A: The official administration instructions for the standard tablet form typically state that the tablet is intended to be swallowed whole. Whether a tablet can be safely altered (crushed or split) often depends entirely on the specific product formulation. Chewable tablet formulations have specific instructions that must be consulted before administration.


Q: Can Postafen affect sleep patterns or cause insomnia?

A: The active ingredient is classified as a central nervous system (CNS) depressant, and drowsiness is a listed side effect. While difficulty falling asleep (insomnia) is not typically listed in the safety profile, any CNS depressant effect has the potential to impact overall sleep quality.


Q: Is there a maximum number of consecutive days Postafen is typically recommended for?

A: Official information describes the drug as being indicated for short-term, as-needed, or prophylactic use. Some regulatory documentation indicates limitations on continuous use, suggesting administration is generally confined to a few consecutive days.


Q: Can Postafen be taken with other antihistamines used for seasonal allergies?

A: Co-administration with other central nervous system (CNS) depressants, which includes some antihistamines used for allergy relief, may result in an additive sedative effect. Official warnings indicate this combination may increase levels of drowsiness or sedation experienced.


Q: Is Postafen the same medication as Meclizine?

A: Postafen is a brand name used in various international regions. In some countries, Postafen refers to the active ingredient Meclizine (Meclozine). In other contexts, the brand name may be used for Buclizine. Both are closely related chemical compounds used for similar purposes.


Q: Does Postafen interact with common over-the-counter pain relievers?

A: Regulatory warnings about interactions focus on additive effects with CNS depressants and anticholinergics. While there are no uniform contraindications for simple over-the-counter pain relievers, regulatory summaries for combination products sometimes list interactions with common analgesics like paracetamol.


Q: Do any official documents warn about taking Postafen with certain foods or drinks, like coffee?

A: Official drug documentation does not typically list specific food-drug interactions for Postafen. Information compiled by drug-food interaction sources suggests that no specific warnings have been found regarding taking this medication with common drinks like coffee.


Q: Are there different brand names that contain the same active ingredient as Postafen?

A: The active ingredients Buclizine and Meclizine are marketed globally under various brand names. These include Bonine, Antivert, Dramamine Less Drowsy, and Sea Legs, with the specific brand name used depending on the region and the exact molecule in the product.


Q: Does Postafen lose its effectiveness if used regularly for a long period of time?

A: Regulatory research summaries note that chronic use of this class of medication has been associated with potential effects on the body's natural compensatory process. However, official information does not explicitly define or confirm a loss of effectiveness, which is sometimes called tolerance.


Q: What should be done if I realize I missed a scheduled time to take Postafen?

A: General patient information outlines a protocol for missed doses, typically suggesting administration when remembered. If it is almost time for the next scheduled dose, skipping the missed dose and resuming the regular schedule is often indicated. Official guidance includes warnings that double doses should be avoided.


Q: Is it necessary to take Postafen with food?

A: Patient information generally states that the medication can be taken with or without food. Taking the dose with food or milk may be suggested if the medication causes mild stomach upset.


Q: Does Postafen cause weight gain?

A: Weight gain itself is not uniformly listed in all official documents. However, some regulatory sources listing potential side effects of the active ingredient include an increase in appetite.


Q: Is Postafen safe to take with common vitamins or herbal supplements?

A: Regulatory warnings indicate that a complete health history, including the use of all vitamins and supplements, must be provided to the prescriber. This is necessary due to the potential for interaction risks that may not be fully documented.


Q: Does Postafen contain common allergens like lactose or gluten?

A: Inactive ingredients, known as excipients, can vary significantly by manufacturer and specific product formulation. The official excipient list for the specific product must be consulted to check for components such as lactose or gluten.


Q: Is Postafen available over-the-counter or does it require a prescription?

A: The regulatory classification for Postafen or its active ingredient Meclizine varies by country, brand, and strength. In some regions, certain Meclizine formulations are classified as Over-the-Counter (OTC), while in other countries, they may require a prescription.


Q: Can Postafen affect blood pressure readings?

A: Low blood pressure, also known as hypotension, is listed as a potential side effect in some product information for the active ingredient Buclizine. This reflects a possible effect on the circulatory system.


Q: What does the official information say about Postafen and heart conditions?

A: Official information notes the need for caution when the drug is considered for individuals with a history of cardiovascular diseases. This constraint is included due to the potential risk of worsening a pre-existing condition.


Q: Is the onset of action different when Postafen is taken on a full stomach versus an empty one?

A: The medication can generally be taken on a full or empty stomach. While there is no direct regulatory data on onset differences with food, patient information includes notes that taking it on an empty stomach may cause mild stomach upset.


Q: Are there any warnings on Postafen about mixing it with natural or herbal products?

A: Regulatory warnings related to interactions require that patients provide a full account of all current medicines, including any herbs and supplements. This is necessary to prevent potential interaction risks that may arise from mixing the drug with natural or herbal products.


Q: Why do some forums say Postafen is a prescription drug while others say it's over-the-counter?

A: The regulatory classification (Prescription-only or Over-the-Counter) for Postafen or its active ingredient Meclizine varies significantly between different countries and regulatory bodies. This difference in status is why public discussions on forums may show conflicting availability information.


Q: Is the active ingredient in Postafen the same as that in Bonine?

A: Bonine is a brand name for the active ingredient Meclizine. Postafen is also a brand name for Meclizine in some regions. Therefore, these two brands often share the same active ingredient.

How should Postafen be stored and disposed of?

How to Store and Dispose of Postafen

Official regulatory guidelines strictly define the conditions necessary to maintain the quality and stability of Postafen, as documented in government sources.

Storage Requirements

Condition Requirement
Temperature Store at room temperature (typically below 25 C or 30 C).
Protection Keep protected from light and moisture.
Prohibited Do not freeze or refrigerate the medicine.
Packaging Keep the tablets in the original blister and outer carton until use.
Shelf-life Do not use Postafen after the expiration date printed on the packaging.
Child Safety Keep this medicine strictly out of the sight and reach of children.

Disposal Instructions

Disposal must adhere to established pharmaceutical waste guidelines to protect the environment. Regulatory instructions state that Postafen must not be discarded with household waste or disposed of via wastewater (e.g., flushing). Unused or expired medication should be returned to a pharmacist or designated collection point for appropriate, environmentally safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Postafen found in:

A-Z Index: